Foghorn Therapeutics Inc.FHTXEarnings & Financial Report
Nasdaq
NextMar 19, 2026
FHTX Q3 2025 Key Financial Metrics
Revenue
$8.2M
Gross Profit
N/A
Operating Profit
$-18.5M
Net Profit
$-15.8M
Gross Margin
N/A
Operating Margin
-226.9%
Net Margin
-194.4%
YoY Growth
4.4%
EPS
$-0.25
Financial Flow
Foghorn Therapeutics Inc. Q3 2025 Financial Summary
Foghorn Therapeutics Inc. reported revenue of $8.2M for Q3 2025, with a net profit of $-15.8M (-194.4% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $8.2M |
|---|---|
| Net Profit | $-15.8M |
| Gross Margin | N/A |
| Operating Margin | -226.9% |
| Report Period | Q3 2025 |
Foghorn Therapeutics Inc. Annual Revenue by Year
Foghorn Therapeutics Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $22.6M).
| Year | Annual Revenue |
|---|---|
| 2024 | $22.6M |
| 2023 | $34.2M |
| 2022 | $19.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8M | $5.0M | $6.9M | $7.8M | $2.9M | $6.0M | $7.6M | $8.2M |
| YoY Growth | 37.9% | -4.9% | 23.0% | -55.3% | -50.5% | 17.9% | 9.7% | 4.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $285.9M | $255.0M | $328.6M | $308.4M | $284.0M | $258.7M | $226.2M | $205.0M |
| Liabilities | $363.1M | $352.5M | $342.9M | $336.7M | $329.5M | $320.3M | $302.9M | $294.6M |
| Equity | $-77.2M | $-97.5M | $-14.3M | $-28.3M | $-45.5M | $-61.7M | $-76.7M | $-89.7M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-27.5M | $-29.3M | $-25.5M | $-21.0M | $-24.5M | $-24.0M | $-21.0M | $-18.9M |